Suggestions
James Hodge
Senior Investigator, National Cancer Institute, NIH. Deputy Chief, Laboratory of Tumor Immunology and Biology
James W. Hodge, Ph.D., M.B.A. is a prominent researcher and senior investigator at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).1 His work focuses on cancer immunology and immunotherapy, with significant contributions to the development of novel cancer vaccines and treatment strategies.12
Professional Role
Dr. Hodge currently holds several important positions at the NCI:
- Senior Investigator
- Deputy Director for Translational Research in the Center for Immuno-Oncology
- Head of the Immunotherapeutics Section
He was awarded tenure in 2016, recognizing his significant contributions to the field.1
Research Focus
Dr. Hodge's research primarily involves:
- Development of novel recombinant vaccines and vaccine combinatorial therapies
- Study of how various treatments (radiation, chemotherapy, targeted therapies) can enhance vaccine efficacy
- Investigation of immunogenic modulation and immune subset conditioning in cancer therapy
His work aims to improve cancer immunotherapy by making tumors more susceptible to immune-mediated destruction.1
Education and Background
- Ph.D. in Comparative and Experimental Medicine from the University of Tennessee
- M.B.A. from George Washington University1
Achievements and Contributions
Dr. Hodge has made significant contributions to cancer immunotherapy, including:
- Design and development of recombinant vectors for tumor antigen delivery
- Use of costimulation to enhance antitumor T-cell responses
- Combination of vaccines with other cancer treatments (radiation, chemotherapy, targeted therapies)1
His research has led to numerous publications in peer-reviewed journals and has advanced the field of cancer immunotherapy.13
